Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (January 2022)
19 slides from Cns Pharmaceuticals's investor presentation, Jan 10, 2022
Slide 1: CNS Pharmaceuticals Investor Presentation January 2022
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP January 2022
Slide 2: Forward-Looking Statements
CNS phar m ac e u t ical s 2 Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statements contained herein other than statements of historical fact, including statements regarding our future resul
Slide 3: Corporate Overview
CNS phar m ac e u t ical s 3 Corporate Overview
Slide 4: Investment Highlights
CNS phar m ac e u t ical s 4 Investment Highlights • Developing anti - cancer drug candidates for the treatment of primary and metastatic brain and CNS cancer • Lead program initially developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Cen
Slide 5: Management Team
CNS phar m ac e u t ical s 5 John M. Climaco, Esq PRESIDENT & CHIEF EXECUTIVE OFFICER Distinctive record of business successes and more than 15 years of experience managing the operations, strategies and finances of public and private companies. Board certified hematologist/medical oncologist with e
Slide 6: Waldemar Priebe, PhD and advisors
CNS phar m ac e u t ical s 6 Waldemar Priebe, PhD Dr. Priebe is a Professor of Medicinal Chemistry in the Section of Immunobiology and Drug Carriers in the Department of Bioimmunotherapy at The University of Texas MD Anderson Cancer Center. Dr. Priebe is the inventor of more than 50 patents and the
Slide 7: Berubicin Overview
CNS phar m ac e u t ical s 7 Berubicin Overview
Slide 8: Glioblastoma Multiforme (GBM)
CNS phar m ac e u t ical s 8 Glioblastoma Multiforme (GBM) 1: https://braintumor.org/take - action/about - gbm/ 2: 8 Major Markets includes USA, France, Germany, Italy, Spain, UK, Japan and urban China 3: Global Data, “Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027” (2017)
Slide 9: Mechanism of Action: Berubicin for the Treatment of GBM
CNS phar m ac e u t ical s 9 Mechanism of Action Berubicin for the Treatment of GBM BERUBICIN IS THE FIRST ANTHRACYCLINE TO APPEAR TO CROSS THE BLOOD - BRAIN BARRIER AND IS DESIGNED TO CONCENTRATE IN TUMOR TISSUE WITHIN THE BRAIN Berubicin has selective uptake in tumor tissue and high brain concentr
Slide 10: Berubicin Phase 1 Results Demonstrated Clinical Response in GBM
CNS phar m ac e u t ical s 10 6 MO. P OST - TR E AT ME N T PR E - TR E AT ME N T PRE - TR E AT ME N T 6 MO. P OST - TR E AT ME N T Berubicin Phase 1 Results Demonstrated Clinical Response in GBM Complete Response at 6 - month Post Treatment* • 44% subjects demonstrated “stable disease or better 1 ”
Slide 11: Potentially Pivotal Study
CNS phar m ac e u t ical s 11 • Dose Berubicin 7.1 mg/m2 IV infusion vs. Lomustine 130 mg/m2 oral • Clinical Sites ~60 centers across; North America, Europe and Asia Pacific • Primary Endpoint Overall Survival (OS) • Secondary Endpoints Duration of Response (DoR); Objective Response Rate (ORR); Indi
Slide 12: Expansion Into Other Cancers
CNS phar m ac e u t ical s 12 Expansion Into Other Cancers INDICATION PATIENT POPULATION ESTIMATED U.S. PATIENTS COMMENTS Primary Brain Tumors Relapsed High Grade Gliomas 15 , 000 Existing data in this population Brain Metastases - Combination with Radiation Therapy Small Cell Lung Cancer 56 , 500 A
Slide 13: Berubicin Intellectual Property
CNS phar m ac e u t ical s 13 Berubicin Intellectual Property • Berubicin’s primary protection is currently the Orphan Drug Designation which provides marketing exclusivity in US market for 7 - years post NDA approval • Additional protection is offered as a New Chemical Entity • CNS is exploring pot
Slide 14: Pipeline and Value Driving Milestones
CNS phar m ac e u t ical s 14 Pipeline and Value Driving Milestones
Slide 15: WP1244 / WP1874 DNA-Binding Agent
CNS phar m ac e u t ical s 15 TECHNOLOGY ORIGINALLY DEVELOPED AND LICENSED FROM THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER • CNS licensed the WP1244 patent portfolio which now includes WP1874, a new formulation which includes a different salt to increase solubility and improve stability • Bel
Slide 16: Value Driving Milestones
CNS phar m ac e u t ical s 16 Value Driving Milestones June 2020 Dec 2020 May 2021 June 2021 Sept 2021 Dec 2021 Dec 2021 Dec 2021 Berubicin ✓ Orphan Drug Designation ✓ IND Accepted for Berubicin ✓ Initiated Potentially Pivotal Global Berubicin trial for GBM ✓ Fast Track Designation ✓ Commencement of
Slide 17: Financial Snapshot
CNS phar m ac e u t ical s 17 1: As of January 6, 2022; 2: As of January 6, 2022 Shares Outstanding 2 ~40M Average Volume 1 ~609K Market Cap 1 ~$30M Cash Balance $8.3M As of September 30, 2021 $11.5M * * Cash balance does not include proceeds from $ 11 . 5 M Private Placement on January 6 , 2022 Fin
Slide 18: Investment Summary
CNS phar m ac e u t ical s 18 Investment Summary DEVELOPING A PIPELINE OF ANTI - CANCER DRUG CANDIDATES FOR THE TREATMENT OF BRAIN CANCERS, AN AREA IN NEED OF NEW INNOVATIONS Lead Program, Berubicin in Ongoing Potentially Pivotal Clinical Trial Berubicin is a novel anthracycline, a class of molecule
Slide 19: Contact details
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP
CNS Pharmaceuticals — Investor Presentation (January 2022) on 6ix